Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 24Lymphoid 21Myeloid 9Plasma cell 6Dermatologic 5Genitourinary 3Thoracic 2Sarcoma 2Classical hematology 2CNS 2Breast 2Other solid neoplasm 1Head & Neck 1

Conditions

Mesothelin-positive Advanced Refractory Solid Tumors 1

Interventions

Cisplatin 7Pemetrexed 6atezolizumab 5Carboplatin 4tislelizumab 3Paclitaxel 3Leucovorin 3Filgrastim 3Etoposide 3vistusertib 2pembrolizumab 2Vincristine 2Topotecan 2Temozolomide 2Tegafur 2Sorafenib 2Irinotecan 2Immunoenzyme Techniques 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2zirconium-89-trastuzumab 1vandetanib 1toripalimab 1temsirolimus 1tanespimycin 1talazoparib 1soblidotin 1selinexor 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × fludarabine phosphate × Other solid neoplasm × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡